LeMaitre Vascular (LMAT)

Executive Summary

LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a global medical device company focused on providing innovative solutions for peripheral vascular disease. Founded by a vascular surgeon in 1983, the company has established a strong legacy with its core valvulotome products and has expanded into arterial reconstruction, biologics, and endovascular procedures. With a valuation of approximately $2.1 billion and a market presence in over 60 countries, LeMaitre benefits from a dedicated sales force and strong relationships with vascular surgeons. The company's strategy centers on niche product development and targeted acquisitions to drive growth. Recent financial performance has been solid, with consistent revenue growth and profitability, supported by an aging population and rising prevalence of peripheral artery disease. LeMaitre's focus on surgeon preference and high-quality products positions it well for continued market share gains in the vascular device space.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for new heparin-bonded vascular graft70% success
• Q4 2026Acquisition of a complementary endovascular device company60% success
• Q2 2027Positive 12-month data from biologic patch clinical trial65% success